March 7th 2014
Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.
December 17th 2013
Two years after the FDA denied a request to expand the indication of finasteride and other 5Î±-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.
October 17th 2012
Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.
February 29th 2012
With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.
August 25th 2011
In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.
August 11th 2011
Dr Jimmie C. Holland was long convinced that psychological status was a critical factor not just in cancer management, but in illness more broadly.
August 8th 2011
Oncologists too often fail to detect the severe distress that can accompany a diagnosis and subsequent treatment.
June 10th 2011
The Cancer Treatment Centers of America program will first be made available to patients with breast, colorectal, lung, and prostate cancers